DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
Eligible age
18+ yrs
Accepts
All genders
Locations
12 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care * Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care
Sponsor: Alnylam Pharmaceuticals
You may qualify if…
- ✓ Has a diagnosis of ATTR-CM
- ✓ Is initiating treatment with vutrisiran or another approved ATTR-CM therapy
You may not qualify if…
- ✕ Is enrolled in an interventional clinical trial
Where it's recruiting
Tucson
Beverly Hills · La Jolla
Naples
Honolulu
Kansas City
Boston
St Louis
New Brunswick
Charlotte
Philadelphia
Memphis
Dallas
Source: ClinicalTrials.gov · NCT07358078 · last updated 2026-10-09